NASDAQ · Biotechnology

UNCY (UNCY) Stock

$5.01 -5.47% NASDAQ: UNCY Healthcare

Valuation

MetricValue
Price$5.01
Market Cap$133.77M
P/E Ratio-4.60
P/B Ratio5.50
P/S Ratio0.00
EPS (TTM)$-1.67
52-Week High$8.74
52-Week Low$3.71
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-90.00%
ROA-55.10%
ROCE-100.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio2.58

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$1.0M$1.0M$0$0
Operating Profit$-9.0M$-18.0M$-21.0M$-32.0M$-30.0M
Net Profit$-10.0M$-18.0M$-31.0M$-37.0M$-27.0M
EPS$-8.60$-1.20$-1.28$-5.60$-1.67
Op Margin—-1898.2%-3077.6%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$19.0M$3.0M$14.0M$32.0M$49.0M
Total Liabilities$2.0M$3.0M$18.0M$24.0M$19.0M
Cash$17.0M$0$10.0M$26.0M$29.0M
Borrowings$0$0$1.0M$1.0M$0

Latest News

Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies Simply Wall St. · Jul 1, 2026 UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval Stocktwits · Jun 30, 2026 Sector Update: Healthcare Stocks Softer Late Afternoon MT Newswires · Jun 30, 2026 Top Midday Decliners MT Newswires · Jun 30, 2026 UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time? Stocktwits · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-6.0M$-16.0M$-18.0M$-29.0M$-31.0M
Investing Cash Flow$0$0$0$0$-12.0M
Financing Cash Flow$0$0$-3.0M$-4.0M$-2.0M
Net Cash Flow$17.0M$-16.0M$9.0M$16.0M$3.0M
Free Cash Flow$-6.0M$-16.0M$-18.0M$-29.0M$-31.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-17.24%
Quick Ratio2.40
Interest Coverage—
Return 1Y11.47%
Return 3Y-58.13%
Return 5Y-83.91%

Ownership

Insiders Held2.36%
Institutions Held32.65%
Institutions Float Held33.44%
Institutional HolderSharesReport Date
Vivo Capital, LLC1,789,9162026-03-31
Millennium Management Llc1,399,3482026-03-31
Octagon Capital Advisors LP1,000,0002026-03-31
Nantahala Capital Management, LLC939,2022026-03-31
Vanguard Capital Management LLC811,4302026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACRV $1.73 +2.37% -0.95 $74.05M 0.00%
BMEA $1.22 +0.00% -1.20 $88.21M 0.00%
CAMP $3.47 +6.12% -1.70 $73.70M 0.00%
CBUS $1.93 +0.00% -0.50 $87.79M 0.00%
HYFT $1.29 -4.44% -1.77 $60.61M 0.00%

About UNCY

UNCY is led by CEO Shalabh K. Gupta, employs 22 people, headquartered in US, publicly traded since 2021.

UNCY stock trades at $5.01 with a market capitalization of $133.77M. The stock is valued at a price-to-earnings (P/E) ratio of -4.60, price-to-book of 5.50, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.71 and $8.74, and currently trades 42.7% below its 52-week high.

On profitability, UNCY generates a return on equity (ROE) of -90.00%, return on capital employed of -100.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides